New cancer pill tested in early trial – but study halted

NCT ID NCT06232408

Terminated Disease control Sponsor: Repare Therapeutics Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-phase trial tested an oral drug called RP-1664 in people with advanced solid tumors that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects. The study was terminated early, so full results may not be available.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RP-1664 (an oral PLK4 inhibitor)
What this could lead to: If successful, this could point toward a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong: This was a very early Phase 1 trial with only 29 participants, and it was terminated, so results may not be available. The drug may not prove effective or safe in larger studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Participating Site 1004

New York, New York, 10065, United States
Participating Site 1008

New York, New York, 10032, United States
Participating Site 1012

New Haven, Connecticut, 06519, United States
Participating Site 1025

San Francisco, California, 94143, United States
Participating Site 4001

Copenhagen, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.